SCHEMBL259844

SCHEMBL259844

COC(=O)c1cc2c(cc1F)NC(=O)C2

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 4/20 0.43
CRBN Q96SW2 3/20 0.41
HDAC3 O15379 1/20 0.40
GAA P10253 1/20 0.40
EIF2AK2 P19525 1/20 0.40
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
AHR P35869 3/20 0.37
CMA1 P23946 2/20 0.37
MAOB P27338 1/20 0.36
EPHX2 P34913 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
MDH2 P40926 1/20 0.36
GSK3B P49841 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577622 0.82 AHR (0.44) SMYD3CRBNGAAEIF2AK2ALDH1A1
SCHEMBL1162689 0.81 SMYD3 (0.43) SMYD3CRBNHDAC3GAAEIF2AK2
SCHEMBL29706811 0.81 CRBN (0.51) CRBN
SCHEMBL19031217 0.81 CRBN (0.45) SMYD3CRBNGAAEIF2AK2ALDH1A1
SCHEMBL19056160 0.79 CRBN (0.41) SMYD3CRBNHDAC3GAAEIF2AK2
SCHEMBL23577762 0.79 SMYD3 (0.49) SMYD3CRBNGAAEIF2AK2AHR
SCHEMBL23011990 0.79 MAP3K5 (0.45) CRBNALDH1A1LMNAGSK3B
SCHEMBL29706757 0.79 MAP3K5 (0.45) CRBNALDH1A1LMNAGSK3B
SCHEMBL259590 0.77 SMYD3 (0.46) SMYD3CRBNHDAC3EIF2AK2ALDH1A1
SCHEMBL23011982 0.76 MAP3K5 (0.45) CRBNHDAC3ALDH1A1LMNACCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 SMYD3 2174/4885CRBN 1371/4885HDAC3 1796/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 SMYD3 2174/4885CRBN 1371/4885HDAC3 1796/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 SMYD3 2174/4885CRBN 1371/4885HDAC3 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.